BXQ-350

COVINGTON, Ky., Dec. 6, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced that its Chairman of the Board, Charles R. Scheper, has been named a Great Living Cincinnatian by The Cincinnati Regional Chamber. Being named a Great Living Cincinnatian is regarded as the preeminent honor in the Cincinnati community. According to The Cincinnati Regional Chamber, Great Living Cincinnatians are recognized by the Cincinnati Regional Chamber for service to the community; business and civic attainment on a local, state, national or international level; leadership; awareness of the needs of others; and distinctive accomplishments that have brought favorable attention to their community, institution, or organization. Mr. Charles "Chuck" Scheper joined Bexion as Chairman of the Board in 2010. He was the Chief Operating Officer at Great American Financial Resources, a $20 billion life and annuity company until his retirement in 2010. Prior to that position, Mr. Scheper was president and chief executive officer of Manhattan National Life Insurance Company and president of Pioneer Financial Services. Chuck is a cancer survivor and his journey to wellness led him to become active in various causes related to cancer, including Cancer Support Community, where he has served as the National Board Chairperson and board member. Currently, he is also the Chair of Catalytic Development Funding Corp of Northern Kentucky and Covington Economic Development Authority. "We are incredibly proud to celebrate our Chairman of the Board, Chuck Scheper, as a Great Living Cincinnatian," said Jim Beach, Bexion's Chief Executive Officer. "This recognition reflects his outstanding leadership and significant impact on our community. Chuck embodies the values we strive for at Bexion and inspires us to continue making a difference in people's lives." More information about the award and upcoming award ceremony in 2025 is available here. About BXQ-350 Bexion's lead drug candidate is BXQ-350, a first-in-class biologic containing the multifunctional sphingolipid activator protein, Saposin C, and a phospholipid. Multiple Phase 1 clinical trials in adult and pediatric patients have demonstrated a robust safety profile for BXQ-350 with evidence of single agent activity across multiple solid tumor types. Additionally, other clinical and non-clinical data suggest BXQ-350 has activity in chemotherapy-induced peripheral neuropathy, an area of high unmet medical need in patients treated with oxaliplatin and other chemotoxic agents. About Bexion Pharmaceuticals Bexion Pharmaceuticals, a clinical-stage biopharmaceutical company, is developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN) with potential portfolio expansion opportunities in other cancers and broader neuropathic pain indications. Bexion has generated data in multiple classes of solid tumors, including colorectal cancer, high-grade gliomas, and pediatric brain tumors. The Company has completed enrollment in the open label portion of its Phase 1b/2 study evaluating BXQ-350 in combination with the standard of care. The Company is now planning to proceed to the randomized, double-blind, placebo-controlled portion of the study. The Company has also completed enrollment in a proof-of-concept trial for the treatment of CIPN. About the Cincinnati Regional Chamber The Cincinnati Regional Chamber is the premier business and civic organization dedicated to growing the vibrancy and economic prosperity of the Cincinnati region. To achieve its vision that Cincinnati is a growing, thriving region where everyone belongs, the Chamber seeks to grow their economy, grow their population, and grow their cultural vibrancy — with the foundation of a strong business community — to foster a welcoming environment for all. The Chamber's membership offerings, signature leadership programs, government and regional advocacy efforts, community events such as BLINK and Oktoberfest as well as key partnerships with organizations like Cincinnati Experience, Cincinnati Compass, Cincinnati Minority Business Accelerator, and the Workforce Innovation Center lead the way in making that vision a reality. For more information, visit . Investor Contact: William Windham Solebury Strategic Communications 646-378-2946 [email protected] Media Contact: Joyce LaViscount Bexion Pharmaceuticals 859-446-7386 [email protected] SOURCE Bexion Pharmaceuticals, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

COVINGTON, Ky., Nov. 18, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced completion of enrollment in the open label portion of Phase 1b/2 ASIST study of BXQ-350 in combination with Standard-of-Care (SOC) for the first line treatment of metastatic colorectal cancer (mCRC). "I am delighted that Bexion has completed enrollment for its Phase 1b/2 clinical trial and am especially pleased my clinical site has made significant contributions toward this effort," said Reema A. Patel, MD, Associate Professor of Medicine at the Markey Cancer Center of the University of Kentucky. "BXQ-350's mechanism of action lends itself to potential benefit in metastatic colorectal patients and peripheral neuropathy. Severe neuropathy is a key reason that patients drop off chemotherapy for colorectal cancer, and BXQ-350 has been shown to possess potential anti-neuropathy properties. I am excited by the potential of BXQ-350 to reduce or even potentially reverse neuropathic pain in these patients." The ASIST study will assess the safety and efficacy of BXQ-350 plus SOC, modified FOLFOX7 (mFOLFOX7) and bevacizumab, in patients with newly diagnosed mCRC. The study is also evaluating whether the administration of BXQ-350 with mFOLFOX7 and bevacizumab may diminish CIPN, enabling participants to receive the total and planned doses of mFOLFOX7. "We extend our gratitude to all the patients, clinical investigators, and site research staff who continue to contribute to the advances we are making," said Jim Beach, Chief Executive Officer of Bexion. "We are excited about advancing to the next stage of clinical development, including further discussions with FDA on study design, and we look forward to providing updates as we reach upcoming milestones in 2025." More information about the clinical trial is available at clinicaltrials.gov (ASIST study; NCT05322590). About BXQ-350 Bexion's lead drug candidate is BXQ-350, a first-in-class biologic containing the multifunctional sphingolipid activator protein, Saposin C, and a phospholipid. Multiple Phase 1 clinical trials in adult and pediatric patients have demonstrated a robust safety profile for BXQ-350 with evidence of single agent activity across multiple solid tumor types. Additionally, other clinical and non-clinical data suggest BXQ-350 has activity in chemotherapy-induced peripheral neuropathy, an area of high unmet medical need in patients treated with oxaliplatin and other chemotoxic agents. About Bexion Pharmaceuticals Bexion Pharmaceuticals, a clinical-stage biopharmaceutical company, is advancing a new class of biologic therapy aimed at treating solid tumors and chemotherapy-induced peripheral neuropathy (CIPN), with the potential to expand its portfolio into additional cancer types and broader neuropathic pain treatments. Bexion has generated positive data across various solid tumor types, including colorectal cancer, high-grade gliomas and pediatric brain tumors. The Company has completed enrollment in the open-label portion of its Phase 1b/2 trial, which evaluates BXQ-350 in combination with the standard of care for newly diagnosed patients with metastatic colorectal cancer (mCRC). Additionally, Bexion has completed patient enrollment in a proof-of-concept study for treating CIPN. Investor Contact: William Windham Solebury Strategic Communications 646-378-2946 [email protected] Media Contact: Joyce LaViscount Bexion Pharmaceuticals 859-446-7386 [email protected] SOURCE Bexion Pharmaceuticals, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED